The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations

Clin Infect Dis. 2005 Jan 15;40(2):225-35. doi: 10.1086/426817. Epub 2004 Dec 21.

Abstract

Background: The purpose of this study was to determine the prevalence of fluoroquinolone resistance and quinolone resistance-determining region (QRDR) mutations among Streptococcus pneumoniae isolates in the United States during the period of 2001-2002. A second objective was to examine the genetic relatedness of pneumococcal isolates with parC and/or gyrA mutations during the period of 1994-2002.

Methods: Susceptibility testing was performed for 1902 S. pneumoniae isolates collected in the United States during the period of 2001-2002. On the basis of the minimum inhibitory concentration (MIC) of ciprofloxacin, 146 isolates were selected from the 2001-2002 study for QRDR analysis of parC, parE, gyrA, and gyrB genes. The genetic relatedness of isolates with parC and/or gyrA mutations from 2001-2002 (n=55) and from 3 US surveillance studies conducted during 1994-2000 (n=56) was determined by pulsed-field gel electrophoresis (PFGE).

Results: Between 1999-2000 and 2001-2002, there was a 2-fold increase in the rate of ciprofloxacin resistance (MIC, >or=4 micro g/mL), from 1.2% to 2.7%, and in the rate of levofloxacin nonsusceptibility (MIC, >or=4 micro g/mL), from 0.6% to 1.3%. The 111 isolates with parC and/or gyrA mutations were assigned to 48 different PFGE types. Forty-four isolates (40%) belonged to 8 PFGE types that were closely related to widespread clones. Fifteen of the 43 levofloxacin-nonsusceptible pneumococci (LNSP) belonged to 4 PFGE types that were closely related to major clones (Spain(23F)-1 [n=6]; Spain(6B)-2 [n=5], Taiwan(19F)-14 [n=2], and Tennessee(23F)-4 [n=2]).

Conclusion: The population of fluoroquinolone-resistant S. pneumoniae in the United States has increased but remains genetically diverse. However, 35% of LNSP were related to widespread pneumococcal clones, increasing the potential for the rapid spread of quinolone resistance in this species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Ciprofloxacin / pharmacology*
  • DNA Gyrase / genetics
  • DNA Topoisomerase IV / genetics
  • Drug Resistance, Bacterial*
  • Humans
  • Levofloxacin*
  • Microbial Sensitivity Tests
  • Mutation
  • Ofloxacin / pharmacology*
  • Pneumococcal Infections / drug therapy
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / microbiology*
  • Population Surveillance
  • Serotyping
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics
  • Time Factors
  • United States

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Levofloxacin
  • Ofloxacin
  • DNA Topoisomerase IV
  • DNA Gyrase